Myelofibrosis and spinal cord ischaemia

• References

• 1 Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost 1997; 78: 617-621.
• 2 Grandone E, Colaizzo D, Tiscia GL. et al. Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation. Thromb Haemost 2008; 99: 640-642.
• 3 Michiels JJ, Berneman Z, Schroyens W. et al. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 2006; 32: 589-604.
• 4 Michiels JJ, Berneman Z, Van Bockstaele D. et al. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006; 32: 174-207.
• 5 Bellucci S, Cassinat B, Bonnin N. et al. The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder. Thromb Haemost 2008; 99: 1119-1120.
• 6 Thiele J, Kvasnicka HM, Werden C. et al. Idiopathic primary osteo-myelofibrosis: a clinico pathological study on 208 patients with special emphasis on evolution of disease features, differenciation from thrombocytopenia and variables of prognostic impact. Leuk Lymphoma 1996; 22: 303-317.
• 7 Hasselbach H. Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol 1990; 34: 291-300.
• 8 Wehmeier A, Suddhoff T, Meierkord F. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Semin Thromb Hemost 1997; 23: 391-402.
• 9 Plume G, Vaya A, Ferrando F. et al. JAK2V617F mutation as a marker of a latent myeloproliferative disorder in a patient with Budd-Chiari syndrome and factor V Leiden mutation. Thromb Haemost 2007; 98: 681-682.
• 10 Randi ML, Lombardi AM, Scapin M. et al. Haemostatic proteins gene polymorphisms in patients with unusual vein thrombosis and Ph-myeloproliferative disorders. Thromb Haemost 2007; 98: 702-704.
• 11 Cancelas JA, Garcia-Avello A, Garcia-Frade LJ. High plasma levels of plasminogen activator inhibitors 1 (PA1) in polycythemia vera and essential thrombocythemia are associated with thrombosis. Thromb Res 1994; 75: 513-520.
• 12 Turritto VT, Weiss HJ. Platelet and red cell involvement in mural thrombogenesis. Ann NY Acad Sci 1983; 416: 363-376.
• 13 Huang PY, Hellums JD. Aggregation and disaggregation kinetics of human blood platelets: Part III. The disaggregation under shear stress of platelet aggregates. Biophys J 1993; 65: 354-361.
• 14 Falanga A, Marchetti M, Evangelista V. et al. Polymorphonuclear leucocyte activation and haemostasis in patients with essential thrombocytemia and polycythemia vera. Blood 2000; 96: 4261-4266.
• 15 Jensen MK, de Nully Brown P, Lund BV. et al. Increases circulating platelet-leucocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Hematol 2001; 66: 143-151.
• 16 Cortelazzo S, Finazzi G, Ruggeri M. et al. Hydro-xyuurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 1132-1136.
• 17 Kees M, Wiesbauer F, Gisslinger B. et al. Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera. Thromb Haemost 2005; 93: 70-75.
• 18 Gruppo Italiano Studio Policitemia.. Policythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656-664.